Alprostadil Injection （Brand name : Kaishi®） is the first lipid microsphere carrier targeting drug approved by SFDA in China. The product is formulated and manufactured by utilizing a unique and advanced technology to produce O/W type of lipid microsphere carriers that enevelope alprostadil drug prodcut. These lipid microsphere of 200nm diameter are prodcued through the course of higly technologically advanced high pressure, isotrope, and emulsification processes. The clinical application of alprostadil injection is broad and mainly used in peripheral pathological changes, microcirulation distributed of the heart and the brain. Kaishi® was launched in China in 1998 and has become one of the best commercilized and soically beneficial drugs in the country.